SCHEMBL24620575

SCHEMBL24620575

Cc1cnc(CNC(=O)c2ccn(S(=O)(=O)c3cccc(Cl)c3)n2)cn1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 2/20 0.40
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
WDR5 P61964 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
NAMPT P43490 1/20 0.38
P2RX3 P56373 1/20 0.38
P2RX2 Q9UBL9 1/20 0.38
GRM4 Q14833 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C1 Q04828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29808214 1.00 ALOX15 (0.42) ALOX15SMN1; SMN2ALDH1A1GRIN1GRIN2A
SCHEMBL22588768 0.88 NPC1 (0.43) SMN1; SMN2GRIN1GRIN2ANPC1RAB9A
SCHEMBL29808041 0.87 GRIN2A (0.53) ALOX15GRIN1GRIN2AWDR5GRM4
SCHEMBL24620645 0.87 GRIN2A (0.53) ALOX15GRIN1GRIN2AWDR5GRM4
SCHEMBL29808368 0.85 EPHX2 (0.39) ALDH1A1GRIN1GRIN2ANPC1RAB9A
SCHEMBL24620569 0.85 EPHX2 (0.39) ALDH1A1GRIN1GRIN2ANPC1RAB9A
SCHEMBL22588777 0.84 P2RX3 (0.41) NAMPTP2RX3P2RX2GRM4
SCHEMBL24620549 0.83 GRM4 (0.44) SMN1; SMN2ALDH1A1GRIN1GRIN2ANPC1
SCHEMBL29808543 0.83 GRM4 (0.44) SMN1; SMN2ALDH1A1GRIN1GRIN2ANPC1
SCHEMBL22588722 0.83 P2RX3 (0.40) ALDH1A1GRIN1GRIN2AP2RX3P2RX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113692405-A Derivatives of N- ((heteroaryl) methyl) -1-tosyl-1H-pyrazole-3-carboxamide as KV3 potassium channel activators for the treatment of neurological or psychiatric disorders H.隆德贝克有限公司 2021-11-23 CN claimed
US-20220220095-A1 N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS H LUNDBECK AS (DK) 2022-07-14 US disclosed
CN-113692405-A Derivatives of N- ((heteroaryl) methyl) -1-tosyl-1H-pyrazole-3-carboxamide as KV3 potassium channel activators for the treatment of neurological or psychiatric disorders H.隆德贝克有限公司 2021-11-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220095-A1 N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS KCNA3, KCNK3, KCND3 ALOX15 3524/4885SMN1; SMN2 1111/4885ALDH1A1 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.